Ani Pharmaceuticals (ANIP) Accumulated Depreciation & Amortization: 2009-2024
Historic Accumulated Depreciation & Amortization for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $44.9 million.
- Ani Pharmaceuticals' Accumulated Depreciation & Amortization rose 36.27% to $44.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $137.8 million, marking a year-over-year increase of 12.01%. This contributed to the annual value of $67.7 million for FY2024, which is 13.28% up from last year.
- Ani Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $44.9 million in Q4 2024, which was up 36.27% from $32.9 million recorded in Q4 2023.
- In the past 5 years, Ani Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $44.9 million during Q4 2024, and its lowest value of $13.9 million during Q1 2020.
- For the 3-year period, Ani Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $31.4 million, with its median value being $30.1 million (2022).
- The largest annual percentage gain for Ani Pharmaceuticals' Accumulated Depreciation & Amortization in the last 5 years was 42.97% (2020), contrasted with its biggest fall of 13.54% (2020).
- Over the past 5 years, Ani Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $17.5 million in 2020, then soared by 30.98% to $23.0 million in 2021, then soared by 42.50% to $32.7 million in 2022, then rose by 0.68% to $32.9 million in 2023, then skyrocketed by 36.27% to $44.9 million in 2024.
- Its last three reported values are $44.9 million in Q4 2024, $32.9 million for Q4 2023, and $27.3 million during Q1 2023.